| Literature DB >> 30430317 |
Valeria A Sansone1, Emilio Albamonte2, Francesca Salmin2, Jacopo Casiraghi2, Alice Pirola2, Massimo Bettinelli2, Fabrizio Rao2, Luca Mancini3, Nicola Tovaglieri3, Fausto Fedeli3, Paolo Stoia3, Maurizio Heinen3, Valeria Cozzi3, Elena Carraro2, Christian Lunetta2, Alessandra Di Bari2, Eugenio Mercuri4.
Abstract
Nusinsersen is now available in Italy for all SMA types. We describe the experience with intrathecal treatment with nusinersen in 50 patients with SMA at the NEMO Center (NEuroMuscular Omniservice Clinical Center) in Milan, a neuromuscular patient-centered clinic hosted within Niguarda Hospital, a National Public General Hospital. Our results indicate that the pathway of care described outweighs the burden due to the repeated intrathecal injections. Irrespective of age and severity, the treatment is feasible, accessible, and replicable provided that there is a multidisciplinary team having experience and training in SMA.Entities:
Keywords: Integrated care; Multidisciplinary; Nusinersen; Spinal muscular atrophy; Spinraza
Mesh:
Substances:
Year: 2018 PMID: 30430317 DOI: 10.1007/s10072-018-3622-9
Source DB: PubMed Journal: Neurol Sci ISSN: 1590-1874 Impact factor: 3.307